- Verubecestat – ALZFORUM
Background MK-8931 is a small-molecule inhibitor of BACE1 and BACE2. BACE1 is the β-secretase enzyme that cleaves the APP protein to release the C99 fragment of APP, which gives rise to various specie …
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β …
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med. 2016 Nov 2;8 (363):363ra150.
At High Doses, BACE1 Inhibitors Hinder Synaptic Plasticity …
Participants in Merck’s Phase 2/3 trial are receiving daily doses of 12, 40, or 60 mg of MK-8931. However, a direct comparison between mouse and human doses is not practical, Filser said, because the …
ALZFORUM | NETWORKING FOR A CURE
Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Paper Alert: Verubecestat Preclinical and Phase 1 Data …
The published data covers the story of verubecestat, aka MK-8931, from its discovery through Phase 1. The researchers report that the compound latches onto the BACE1 catalytic site with exquisite sens …
BACE Inhibitor Heads for Phase 2/3 Trials | ALZFORUM
The news comes after Merck’s December 2013 announcement that its inhibitor MK-8931 had cleared safety hurdles in its Phase 2/3 study (see Dec 2013 news story). Other BACE inhibitors are in earlier sta …
Vanquishing Brain Cancer: A New Mission for BACE inhibitors?
First author Kui Zhai and colleagues happened upon verubecestat, aka MK-8931, while searching for ways to rouse TAMs into destroying glioma cells. The BACE inhibitor emerged as a top candidate in a sc …
Therapeutics Search | ALZFORUM
Amyloid-Related Small Molecule Alzheimer's Disease
Therapeutics Search | ALZFORUM
How would you like to share? Facebook Twitter LinkedIn Back to the Top Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 …
Lanabecestat – ALZFORUM
AZD3293/lanabecestat inhibits both the BACE1 and 2 enzymes. It is administered in tablet form. This compound's in vitro and in vivo pharmacologic profile in primary cortical neurons, mice, guinea …
コメント